Skip to main content
B

BrightPath Biotherapeutics Co., Ltd. — Investor Relations & Filings

Ticker · 4594 ISIN · JP3274140007 T Manufacturing
Open in API
Filings indexed 69 across all filing types
Latest filing 2021-06-25 Governance Information
Country JP Japan
Listing T 4594

About BrightPath Biotherapeutics Co., Ltd.

https://www.brightpathbio.com/english/

BrightPath Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company's core technology is its iPS-NKT platform, a novel allogeneic cell therapy that utilizes induced pluripotent stem cells (iPSCs) to produce large, homogeneous quantities of natural killer T (NKT) cells for cancer treatment. This proprietary approach is designed to overcome the natural scarcity of NKT cells, enabling the therapeutic application of their multifaceted anti-tumor effects. In addition to its cell therapy program, the company's development pipeline includes cancer peptide vaccines and immuno-modulating antibodies.

Recent filings

Filing Released Lang Actions
内部統制報告書－第18期(令和2年4月1日－令和3年3月31日)
Governance Information Classification · 1% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act in Japan. It details the company's framework, scope, and results regarding internal controls over financial reporting. Since this is a standalone regulatory filing concerning audit-related internal control assessments and does not constitute a full Annual Report (10-K) or a simple announcement, it falls under the 'Audit Report / Information' category.
2021-06-25 Japanese
有価証券報告書－第18期(令和2年4月1日－令和3年3月31日)
Annual Report Classification · 1% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which translates to 'Annual Securities Report'. This is the standard Japanese regulatory filing equivalent to a 10-K in the United States, containing comprehensive financial statements, business descriptions, and management analysis for the fiscal year ending March 31, 2021. It is not an announcement or a summary, but the full report itself. FY 2021
2021-06-25 Japanese
四半期報告書－第18期第3四半期(令和2年10月1日－令和2年12月31日)
Interim / Quarterly Report Classification · 1% confidence The document is a '四半期報告書' (Quarterly Report) filed by BrightPath Biotherapeutics Co., Ltd. with the Kanto Local Finance Bureau. It contains detailed financial statements (balance sheets, etc.), management analysis of financial results, and business operations for the third quarter of the 18th fiscal period (ending December 31, 2020). As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data, it is classified as an Interim/Quarterly Report. 9M 2021
2021-02-12 Japanese
四半期報告書－第18期第2四半期(令和2年7月1日－令和2年9月30日)
Interim / Quarterly Report Classification · 1% confidence The document is a '四半期報告書' (Quarterly Report) filed by BrightPath Biotherapeutics Co., Ltd. with the Kanto Local Finance Bureau in Japan. It contains detailed financial statements, management analysis (MDA), and operational updates for the second quarter of the 18th fiscal period (ending September 30, 2020). As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data, it is classified as an Interim/Quarterly Report (IR). H1 2021
2020-11-13 Japanese
四半期報告書－第18期第1四半期(令和2年4月1日－令和2年6月30日)
Interim / Quarterly Report Classification · 1% confidence The document is a '四半期報告書' (Quarterly Report) filed by BrightPath Biotherapeutics Co., Ltd. with the Kanto Local Finance Bureau. It contains detailed financial statements, management analysis of financial results, and information on business operations for the first quarter of the 18th fiscal year (April 1, 2020, to June 30, 2020). This fits the definition of an Interim/Quarterly Report (IR). Q1 2020
2020-08-14 Japanese
有価証券報告書－第17期(平成31年4月1日－令和2年3月31日)
Annual Report Classification · 1% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which translates to 'Annual Securities Report'. This is the standard Japanese regulatory filing equivalent to the US 10-K, covering the fiscal year (第17期, 2019-04-01 to 2020-03-31), including financial statements, business overview, and management analysis. It is a comprehensive annual report, not an announcement or a summary. FY 2019
2020-06-29 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.